Need help finding what you are looking for?
Contact Us
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1831659
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1831659
Immuno-Oncology Market Size, Share, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region - Market Forecast, 2025-2034
PUBLISHED:
PAGES: 128 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The Immuno-oncology market size is expected to reach USD 216.34 billion by 2034, according to a new study by Polaris Market Research. The report "Immuno-Oncology Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Immuno-oncology can be defined as an advanced therapeutic approach that empowers the body's immune system to recognize and combat cancer cells with precision. This market is driven by the rapid adoption of combination immunotherapies, which integrate multiple treatment modalities to enhance efficacy, overcome resistance mechanisms, and provide more durable clinical responses. These approaches are gaining traction as they deliver improved patient outcomes compared to monotherapies, supported by ongoing advancements in molecular biology and immune profiling. The increasing success of such combinations is driving research investment and expanding the scope of application across various cancer types, reinforcing their role as a cornerstone of the market's evolution.
The immuno-oncology market is further influenced by the growing focus on biomarker-driven treatment strategies, enabling the development of highly targeted and personalized therapies. Clinicians can better predict patient response and tailor treatments accordingly by leveraging biomarkers such as genetic mutations, immune signatures, and tumor microenvironment characteristics. This precision-focused approach optimizes therapeutic effectiveness and also minimizes adverse effects, improving overall treatment tolerability. Additionally, the integration of biomarker research into drug development pipelines is accelerating innovation and enabling a shift toward more individualized cancer care solutions within the immuno-oncology landscape.
Immuno-Oncology Market Report Highlights
In terms of treatment approaches, the checkpoint inhibitors led with 57.42% revenue share in 2024, driven by their durable clinical responses across cancers through PD-1/PD-L1 and CTLA-4 targeting.
Based on novel target type, the A2AR antagonist/CD73i therapies segment is expected to register the highest CAGR of 16.1% during the forecast period by disrupting adenosine-mediated immunosuppression in tumors.
In 2024, North America dominated with 31.27% global share, supported by advanced healthcare systems and biopharma innovation hubs.
The Asia Pacific Immuno-Oncology Market would report a CAGR of 16.3% by 2034, fueled by rising treatment access and healthcare investments.
A few global key Immuno-Oncology Market players include Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline Plc; Incyte Corporation; Janssen Biotech, Inc; Merck & Co.; Novartis AG; Pfizer Inc.; Roche Holding AG; Sanofi; and Takeda Pharmaceuticals.
Polaris Market Research has segmented the Immuno-Oncology Market report on the basis of treatment approaches, novel target type, tumor or cancer type, and region:
By Treatment Approaches Outlook (Revenue, USD Billion, 2020-2034)
Monoclonal Antibodies
Therapeutic Vaccines
Checkpoint Inhibitors
Cytokines
By Novel Target Type Outlook (Revenue, USD Billion, 2020-2034)
IDO1i
LAG-3 CPI
Oncolytic Virus
STING Agonist
TLR Agonist
HDACi
TIL
VEGFi
MEKi
TIGIT
CPI
GITR Agonist
TGF-b trap
A2AR Antagonist/CD73i
By Tumor or Cancer Type Outlook (Revenue, USD Billion, 2020-2034)
Melanoma
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Head, Face & Neck Cancer
Bladder Cancer
Classical Hodgkin's Lymphoma
Merkel Cell Carcinoma
Other Cancer Types
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Product Code: PM1083
Table of Contents
Chapter 1. Introduction
- 1.1 Report Description
Chapter 2. Research Methodology Overview
- 2.1 Research Process
- 2.1.1 Information procurement
- 2.1.2 Purchased database:
- 2.1.3 Polaris Market Research's internal database
- 2.2 Research Methodology
- 2.3 Research Scope & Assumptions
- 2.4 List of Data Sources
Chapter 3. Executive Summary
- 3.1 Market Snapshot - Key Takeaways
- 3.2 Immuno-Oncology (IO) regional market place: Key takeaways
Chapter 4. Immuno-Oncology (IO) Market Insights
- 4.1 Immuno-Oncology (IO) - Market segmentation & scope
- 4.1.1 Market definitions
- 4.2 Immuno-Oncology (IO) - Market size and growth prospects
- 4.3 Immuno-Oncology (IO) - Value chain analysis
- 4.4 Market Dynamics
- 4.4.1 Drivers
- 4.4.1.1 Increasing introduction of unconventional and advanced treatment techniques
- 4.4.1.2 Rapidly growing population of various cancer infected patients
- 4.4.2 Restraints
- 4.4.2.1 Limited access and awareness about immunotherapy
- 4.4.3 Opportunity analysis: Immunology-oncology market
- 4.4.3.1 Increasing demand for improved cancer care by patients
- 4.4.1 Drivers
- 4.5 Porter's Five Forces Analysis
- 4.6 Immuno-Oncology (IO) - Company Market Share Analysis, 2024
- 4.7 PEST Analysis: Immuno-Oncology Market
- 4.8 Five forces shaping the immuno-oncology market
- 4.9 COVID-19 Impact Analysis
Chapter 5. Immuno-Oncology Market Estimates and Forecast, by Treatment Approaches
- 5.1 Market size by treatment type
- 5.2 Monoclonal Antibodies
- 5.2.1 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034
- 5.3 Therapeutic Vaccines
- 5.3.1 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034
- 5.4 Checkpoint Inhibitors
- 5.4.1 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034
- 5.5 Cytokines
- 5.5.1 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034
Chapter 6. Immuno-Oncology Market Estimates and Forecast, by Novel Target Type
- 6.1 Market size by novel target type
- 6.2 IDO1i
- 6.2.1 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034
- 6.3 LAG-3 CPI
- 6.3.1 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034
- 6.4 Oncolytic virus
- 6.4.1 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034
- 6.5 STING agonist
- 6.5.1 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034
- 6.6 TLR agonist
- 6.6.1 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034
- 6.7 HDACi
- 6.7.1 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034
- 6.8 TIL
- 6.8.1 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034
- 6.9 VEGFi
- 6.9.1 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034
- 6.10 MEKi
- 6.10.1 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034
- 6.11 TIGIT
- 6.11.1 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034
- 6.12 CPI
- 6.12.1 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034
- 6.13 GITR agonist
- 6.13.1 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034
- 6.14 TGF-b trap
- 6.14.1 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034
- 6.15 A2AR antagonist/CD73i
- 6.15.1 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034
Chapter 7. Immuno-Oncology Market Estimates and Forecast, by Tumor or Cancer Type
- 7.1 Market size by tumor or cancer type
- 7.2 Melanoma
- 7.2.1 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034
- 7.3 Non-small cell lung cancer
- 7.3.1 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034
- 7.4 Renal cell carcinoma
- 7.4.1 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034
- 7.5 Head, face & neck cancer
- 7.5.1 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034
- 7.6 Bladder cancer
- 7.6.1 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034
- 7.7 Classical hodgkin's lymphoma
- 7.7.1 Global Immuno-Oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2021-2034
- 7.8 Merkel cell carcinoma
- 7.8.1 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034
- 7.9 Other cancer types
- 7.9.1 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034
Chapter 8. Immuno-Oncology Market Estimates and Forecast, by Region
- 8.1 Market size by region
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 France
- 8.3.2 Germany
- 8.3.3 Italy
- 8.3.4 Spain
- 8.3.5 UK
- 8.3.6 Austria
- 8.3.7 Netherlands
- 8.3.8 Rest of EU
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Indonesia
- 8.4.5 South Korea
- 8.4.6 Malaysia
- 8.4.7 RoAPAC
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of LATAM
- 8.6 Middle East & Africa
- 8.6.1 Israel
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 UAE
- 8.6.5 Rest of Middle East & Africa
Chapter 9. Competitive Landscape
- 9.1 Strategy framework
- 9.2 Strategies Adopted By Major Players During COVID-19 Pandemic
- 9.3 Competitive Environment
- 9.4 Merger & Acquisition Analysis
Chapter 10. Company Profiles
- 10.1 Bristol Myers Squibb
- 10.1.1 Company Overview
- 10.1.2 Financial Performance (Revenue)
- 10.1.3 Product Benchmarking
- 10.1.4 Recent Developments
- 10.2 Merck & Co.
- 10.2.1 Company Overview
- 10.2.2 Financial Performance (Revenue)
- 10.2.3 Product Benchmarking
- 10.2.4 Recent Developments
- 10.3 AstraZeneca
- 10.3.1 Company Overview
- 10.3.2 Financial Performance (Revenue)
- 10.3.3 Product Benchmarking
- 10.3.4 Recent Developments
- 10.4 Roche Holding AG
- 10.4.1 Company Overview
- 10.4.2 Financial Performance (Revenue)
- 10.4.3 Product Benchmarking
- 10.4.4 Recent Developments
- 10.5 Pfizer Inc.
- 10.5.1 Company Overview
- 10.5.2 Financial Performance (Revenue)
- 10.5.3 Product Benchmarking
- 10.5.4 Recent Developments
- 10.6 Incyte Corporation
- 10.6.1 Company Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Benchmarking
- 10.6.4 Recent Developments
- 10.7 Amgen, Inc.
- 10.7.1 Company Overview
- 10.7.2 Financial Performance (Revenue)
- 10.7.3 Product Benchmarking
- 10.7.4 Recent Developments
- 10.8 Eli Lilly and Company
- 10.8.1 Company Overview
- 10.8.2 Financial Performance (Revenue)
- 10.8.3 Product Benchmarking
- 10.8.4 Recent Developments
- 10.9 GlaxoSmithKline Plc
- 10.9.1 Company Overview
- 10.9.2 Financial Performance (Revenue)
- 10.9.3 Product Benchmarking
- 10.9.4 Recent Developments
- 10.10 Janssen Biotech, Inc
- 10.10.1 Company Overview
- 10.10.2 Jonson & Johnson Financial Performance (Revenue)
- 10.10.3 Product Benchmarking
- 10.10.4 Recent Developments
- 10.11 Novartis AG
- 10.11.1 Company Overview
- 10.11.2 Financial Performance (Revenue)
- 10.11.3 Product Benchmarking
- 10.11.4 Recent Developments
- 10.12 Sanofi
- 10.12.1 Company Overview
- 10.12.2 Financial Performance (Revenue)
- 10.12.3 Product Benchmarking
- 10.12.4 Recent Developments
- 10.13 Takeda Pharmaceuticals
- 10.13.1 Company Overview
- 10.13.2 Financial Performance (Revenue)
- 10.13.3 Product Benchmarking
- 10.13.4 Recent Developments
Product Code: PM1083
List of Tables
- Table 1 Global Immuno-Oncology market estimates & forecasts by region, 2021-2034, (USD Billion)
- Table 2 Drivers and inhibitors for global immuno-oncology market:
- Table 3 Restraints for global immuno-oncology market:
- Table 4 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
- Table 5 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
- Table 6 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
- Table 7 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
- Table 8 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034, (USD Billion)
- Table 9 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034, (USD Billion)
- Table 10 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034, (USD Billion)
- Table 11 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034, (USD Billion)
- Table 12 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034, (USD Billion)
- Table 13 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034, (USD Billion)
- Table 14 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034, (USD Billion)
- Table 15 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034, (USD Billion)
- Table 16 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034, (USD Billion)
- Table 17 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034, (USD Billion)
- Table 18 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034, (USD Billion)
- Table 19 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034, (USD Billion)
- Table 20 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034, (USD Billion)
- Table 21 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034, (USD Billion)
- Table 22 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034, (USD Billion)
- Table 23 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034, (USD Billion)
- Table 24 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034, (USD Billion)
- Table 25 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034, (USD Billion)
- Table 26 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034, (USD Billion)
- Table 27 Global Immuno-Oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2021-2034, (USD Billion)
- Table 28 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034, (USD Billion)
- Table 29 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034, (USD Billion)
- Table 30 North America Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
- Table 31 North America Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 32 North America Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 33 North America Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 34 U.S. Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 35 U.S. Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 36 U.S. Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 37 Canada Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 38 Canada Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 39 Canada Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 40 Europe Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
- Table 41 Europe Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 42 Europe Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 43 Europe Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 44 France Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 45 France Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 46 France Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 47 Germany Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 48 Germany Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 49 Germany Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 50 Italy Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 51 Italy Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 52 Italy Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 53 Spain Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 54 Spain Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 55 Spain Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 56 UK Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 57 UK Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 58 UK Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 59 Austria Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 60 Austria Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 61 Austria Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 62 Netherlands Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 63 Netherlands Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 64 Netherlands Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 65 Rest of EU Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 66 Rest of EU Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 67 Rest of EU Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 68 Asia Pacific Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
- Table 69 Asia Pacific Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 70 Asia Pacific Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 71 Asia Pacific Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 72 China Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 73 China Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 74 China Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 75 India Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 76 India Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 77 India Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 78 Japan Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 79 Japan Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 80 Japan Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 81 Indonesia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 82 Indonesia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 83 Indonesia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 84 South Korea Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 85 South Korea Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 86 South Korea Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 87 Malaysia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 88 Malaysia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 89 Malaysia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 90 RoAPAC Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 91 RoAPAC Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 92 RoAPAC Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 93 Latin America Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
- Table 94 Latin America Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 95 Latin America Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 96 Latin America Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 97 Brazil Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 98 Brazil Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 99 Brazil Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 100 Mexico Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 101 Mexico Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 102 Mexico Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 103 Argentina Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 104 Argentina Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 105 Argentina Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 106 Rest of LATAM Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 107 Rest of LATAM Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 108 Rest of LATAM Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 109 Middle East & Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 110 Middle East & Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 111 Middle East & Africa Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 112 Middle East & Africa Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 113 Israel Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 114 Israel Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 115 Israel Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 116 Saudi Arabia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 117 Saudi Arabia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 118 Saudi Arabia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 119 South Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 120 South Africa Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 121 South Africa Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 122 UAE Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 123 UAE Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 124 UAE Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
- Table 125 RoMEA Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
- Table 126 RoMEA Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
- Table 127 RoMEA Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
List of Figures
- Figure 1. Research process
- Figure 2. Information procurement
- Figure 3. Global Immuno-Oncology Market, 2021-2034 (USD Billion)
- Figure 4. Porter's Five Forces Analysis
- Figure 5. PEST Analysis: Immuno-Oncology Market
- Figure 6. Immuno-Oncology market share by treatment type/process, 2021-2034
- Figure 7. Immuno-Oncology market share by novel target, 2024 & 2034
- Figure 8. Immuno-Oncology market share by tumour or cancer type, 2021-2034
- Figure 9. Immuno-Oncology market share by region, 2024 & 2034
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.